<u> </u>	PTO/SB/08 A & B (modified			
• • • • • • • • • • • • • • • • • • • •	Complete if Known			
Substitute for form 1449 A & B/PTO	Application Number	09/988,285		
INFORMATION DISCLOSURE	Confirmation Number	8475		
STATEMENT BY APPLICANT	Filing Date	November 19, 2001		
	First Named Inventor	Johannes Henricus Matthias SCHELLENS		
OIPE (use as many sheets as necessary)	Art Unit	1614		
	Examiner Name	Not Yet Assigned		
Sheet 1 of 1	Attorney Docket Number	Q67353		

星 5		U.S. 1	PATENT DOCUME	ENTS
Examiner TRADE No.	Document 1	Number	Publication Date MM-DD-YYYY	
	Number	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document
	US			
	US			
	US		***	· · · · · · · · · · · · · · · · · · ·
	US			
	US			
	US			- Wells
	US			

			I	FOREIGN PA	ATENT DOCUMEN	ITS	
Examiner Initials* Cite No. 1 Country Code 3 Number 4 Kind Code 5 (if known)	F	oreign Patent Doc	ument	Publication Date	Name of Patentee or		
	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶				
		WO	99/40110		08/12/99		
						RECEIVE	
				<u> </u>		TOTIVED	
						APR 0 1 2003	
			,			TECH CENTER 1800/2900	
····	<u> </u>					2 - MEN 1600/2900	
							-

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation	
		International Search Report		
		Rabindran, S.K., "Fumitremorgin C reverses a novel multidrug resistance mechanism in mitoxantrone-selected cells", Wyeth-Ayerst Research, XP-000878953		
		Rabindran, S.K., "Reversal of a Novel Multidrug Resistance Mechanism in Human Colon Carcinama Cells by Fumitremorgin", Cancer Research 585850-5858, December 15, 1998, XP-000876633		
		Hazlehurst, L.A., "Multiple Mechanism Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line", Cancer Research 59, 1021-1028, March 1, 1999, XP-000876632		

		T	
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In respplication of

Johannes Henricus Matthias SCHELLENS, et al.

Appln. No. 09/988,285

Group Art Unit: 1614

Confirmation No.: 8475

Examiner: Not Yet Assigned

Filed: November 19, 2001

For:

A METHOD OF IMPROVING BIOAVAILABILITY OF ORALLY ADMINISTERED DRUGS, A METHOD OF SCREENING FOR ENHANCERS OF SUCH BIOAVAILABILITY AND NOVEL PHARMACEUTICAL COMPOSITIONS FOR ORAL DELIVERY OF DRUGS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a Foreign Patent Office in a counterpart application citing such documents, together with an English-language version (if not already included) of that portion of the Communication indicating the degree of relevance found by the foreign office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

SUGHRUE MION, PLLC 2100 Pennsylvania Avenue, N.W. Washington, D.C. 20037-3213 Telephone: (202) 203 7060

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

RJS/amt

Date: March 7, 2002